Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Azad, A K M ^a   Lawen, Alfons ^a   Keith, Jonathan M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; LYMPHOID ENHANCER FACTOR 1; MESSENGER RNA; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; ANTINEOPLASTIC AGENT;

ARTICLE; BAYES THEOREM; BREAST CANCER; BREAST CANCER CELL LINE; CANCER RESISTANCE; GENE EXPRESSION; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PROBABILITY;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROBABILITY;

EID: 85015275888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0173331     Document Type: Article

References (113)

1. Brivanlou AH, Darnell JE. Signal transduction and the control of gene expression. Science. 2002; 295 (5556):813-818. https://doi.org/10.1126/science.1066355 PMID: 11823631
2. Sarkar S, Mandal M. Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer. Breast Cancer (Auckl). 2009; 3:47-60. PMID: 21556249
3. Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharmaceutica Sinica B. 2015; 5(5):390-401. https://doi.org/10.1016/j.apsb.2015.07.001 PMID: 26579470
4. Yamaguchi H, Chang SS, Hsu JL, Hung MC. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene. 2014; 33(9):1073-1081. https://doi.org/10.1038/onc.2013.74 PMID: 23542173
5. Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Rep. 2015; 11(3):390-404. https://doi.org/10.1016/j.celrep.2015.03.037 PMID: 25865888
6. Clark GJ, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat. 1995; 35(1):133-144. https://doi.org/10.1007/BF00694753 PMID: 7612899
7. Shi I, Sadraei N Hashemi, Duan ZH, Shi T. Aberrant signaling pathways in squamous cell lung carcinoma. Cancer Inform. 2011; 10:273-285. https://doi.org/10.4137/CIN.S8283 PMID: 22174565
8. Mao H, Lebrun DG, Yang J, Zhu VF, Li M. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012; 30(1):48-56. https://doi.org/10.3109/07357907.2011.630050 PMID: 22236189
9. McCleary-Wheeler AL, McWilliams R, Fernandez-Zapico ME. Aberrant signaling pathways in pancreatic cancer: a two compartment view. Mol Carcinog. 2012; 51(1):25-39. https://doi.org/10.1002/mc.20827 PMID: 22162229
10. Azad A, Lawen A, Keith J. Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling. BMC Syst Biol. 2015; 9(1):2. https://doi.org/10.1186/s12918-014-0135-x PMID: 25599599
11. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine. 2005; 352(8):786-792. https://doi.org/10.1056/NEJMoa044238 PMID: 15728811
12. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, et al. Resiliency and vulnerability in the HER2-HER3tumorigenic driver. Sci Transl Med. 2010; 2(16):16ra7. https://doi.org/10.1126/scitranslmed.3000389 PMID: 20371474
13. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, Chakrabarty A, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA. 2011; 108(12):5021-5026. https://doi.org/10.1073/pnas.1016140108 PMID: 21385943
14. Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, et al. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochem Biophys Res Commun. 2011; 407(1):219-224. https://doi.org/10.1016/j.bbrc.2011.03.002 PMID: 21377448
15. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, et al. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011; 13(4):R84. https://doi.org/10.1186/bcr2936 PMID: 21884573
16. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit RevOncog. 2012; 17(1):1-16. https://doi.org/10.1615/CritRevOncog.v17.i1.20 PMID: 22471661
17. Kolch W, Halasz M, Granovskaya M, Kholodenko BN. The dynamic control of signal transduction networks in cancer cells. Nat Rev Cancer. 2015; 15(9):515-527. https://doi.org/10.1038/nrc3983 PMID: 26289315
18. Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012; 26(7):641-650. https://doi.org/10.1101/gad.186965.112 PMID: 22474259
19. Komurov K, Tseng JT, Muller M, Seviour EG, Moss TJ, Yang L, et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Molecular Systems Biology. 2012; 8(1). https://doi.org/10.1038/msb.2012.25 PMID: 22864381
20. Locasale JW. Metabolic rewiring drives resistance to targeted cancer therapy. Mol Syst Biol. 2012; 8:597. https://doi.org/10.1038/msb.2012.30 PMID: 22806144
21. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, et al. De-Repression of PDGFR-beta Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients. Cancer Discovery. 2013; 3(5):534-547. https://doi.org/10.1158/2159-8290.CD-12-0502 PMID: 23533263
22. Saul ZM, Filkov V. Exploring biological network structure using exponential random graph models. Bioinformatics. 2007; 23(19):2604-2611. https://doi.org/10.1093/bioinformatics/btm370 PMID: 17644557
23. Bulashevska S, Bulashevska A, Eils R. Bayesian statistical modelling of human protein interaction network incorporating protein disorder information. BMC Bioinformatics. 2010; 11:46. https://doi.org/10.1186/1471-2105-11-46 PMID: 20100321
24. Holland PW, Leinhardt S. An Exponential Family of Probability Distributions for Directed Graphs. Journal of the American Statistical Association. 1981; 76(373):33-50. https://doi.org/10.2307/2287042
25. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009; 325 (5947):1555-1559. https://doi.org/10.1126/science.1174229 PMID: 19661383
26. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-1033. https://doi.org/10.1126/science.1160809 PMID: 19460998
27. Roberts CG, Millar EK, O'Toole SA, McNeil CM, Lehrbach GM, Pinese M, et al. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene. 2011; 30(28):3186-3197. https://doi.org/10.1038/onc.2011.36 PMID: 21383694
28. Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv Cancer Res. 2002; 85:145-174. https://doi.org/10.1016/S0065-230X(02)85005-9 PMID: 12374285
29. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother. 2004; 53(3):153-159. https://doi.org/10.1007/s00262-003-0474-8 PMID: 14749900
30. Sharifnia T, Rusu V, Piccioni F, Bagul M, Imielinski M, Cherniack AD, et al. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci USA. 2014; 111(52):18661-18666. https://doi.org/10.1073/pnas.1412228112 PMID: 25512530
31. Tian Y, Zhang B, Hoffman EP, Clarke R, Zhang Z, Shih Ie M, et al. Knowledge-fused differential dependency network models for detecting significant rewiring in biological networks. BMC Syst Biol. 2014; 8:87. https://doi.org/10.1186/s12918-014-0087-1 PMID: 25055984
32. Jung S, Kim S. EDDY: a novel statistical gene set test method to detect differential genetic dependencies. Nucleic Acids Res. 2014; 42(7):e60. https://doi.org/10.1093/nar/gku099 PMID: 24500204
33. Elo LL, Jarvenpaa H, Oresic M, Lahesmaa R, Aittokallio T. Systematic construction of gene coexpression networks with applications to human T helper cell differentiation process. Bioinformatics. 2007; 23(16):2096-2103. https://doi.org/10.1093/bioinformatics/btm309 PMID: 17553854
34. Wang E. Human signaling network; 2014. Database: Cancer Systems Biology and Bioinformatics. Available from: http://www.cancer-systemsbiology.org/dataandsoftware.htm
35. Dhomen NS, Mariadason J, Tebbutt N, Scott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit RevOncog. 2012; 17(1):31-50. https://doi.org/10.1615/CritRevOncog.v17.i1.40 PMID: 22471663
36. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23(11):2445-2459. https://doi.org/10.1200/JCO.2005.11.890 PMID: 15753456
37. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007; 4(10):e315. https://doi.org/10.1371/journal.pmed.0040315 PMID: 17973572
38. Toyooka S, Date H, Uchida A, Kiura K, Takata M. The Epidermal Growth Factor Receptor D761Y Mutation and Effect of Tyrosine Kinase Inhibitor. American Association for Cancer Research. 2007; 13(11):3431-3431. https://doi.org/10.1158/1078-0432.CCR-07-0070 PMID: 17545553
39. Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res. 2008; 14(22):7519-7525. https://doi.org/10.1158/1078-0432.CCR-08-0151 PMID: 19010870
40. Landi L, Cappuzzo F. HER2and lung cancer. Expert Review of Anticancer Therapy. 2013; 13(10):1219-28. https://doi.org/10.1586/14737140.2013.846830 PMID: 24134423
41. Luo M, Fu LW. Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. Am J Cancer Res. 2014; 4(6):608-628. PMID: 25520855
42. Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, et al. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal. 2009; 2(102):er11. PMID: 20039471
43. Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, et al. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle. 2015; 14(4):648-655. https://doi.org/10.4161/15384101.2014.994966 PMID: 25590338
44. Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, et al. Amplification of CRKL induces transformation and EGFR inhibitor resistance in human non small cell lung cancers. Cancer Discovery. 2011;.
45. Azuaje F, Tiemann K, Niclou SP. Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma. Cell Commun Signal. 2015; 13:23. https://doi.org/10.1186/s12964-015-0098-6 PMID: 25885672
46. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008; 118(7):2609-2619. https://doi.org/10.1172/JCI34588 PMID: 18568074
47. Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, et al. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol (Dordr). 2013; 36(4):277-288. https://doi.org/10.1007/s13402-013-0133-9
48. Baker AT, Zlobin A, Osipo C. Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. Front Oncol. 2014; 4:360. https://doi.org/10.3389/fonc.2014.00360 PMID: 25566499
49. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta. 2010; 1806(2):258-267. https://doi.org/10.1016/j.bbcan.2010.06.001 PMID: 20600632
50. Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther. 2011; 10(1):9-15. https://doi.org/10.1158/1535-7163.MCT-10-0677 PMID: 20971825
51. Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL, Ford CE. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer. 2013; 13:174. https://doi.org/10.1186/1471-2407-13-174 PMID: 23547709
52. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res. 2010; 30(6):2041-2048. PMID: 20651349
53. Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther. 2011; 4:43-58. https://doi.org/10.2147/OTT.S18155 PMID: 21691577
54. Chatterjee S, Heukamp LC, Siobal M, Schottle J, Wieczorek C, Peifer M, et al. Tumor VEGF: VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. The Journal of Clinical Investigation. 2013; 123(4):1732-1740. https://doi.org/10.1172/JCI65385 PMID: 23454747
55. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, et al. Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. Clinical Cancer Research. 2008; 14(16):5069-5080. https://doi.org/10.1158/1078-0432.CCR-07-4905 PMID: 18694994
56. Azuma K, Kawahara A, Sonoda K, Nakashima K, Tashiro K, Watari K, et al. FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor. Oncotarget. 2014; 5(15). https://doi.org/10.18632/oncotarget.1866 PMID: 25115383
57. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol. 2009; 11(12):1444-1450. https://doi.org/10.1038/ncb1993 PMID: 19935651
58. Zhao Y, Yang X. The Hippo pathway in chemotherapeutic drug resistance. Int J Cancer. 2015; 137(12):2767-2773. https://doi.org/10.1002/ijc.29293 PMID: 25348697
59. Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, et al. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene. 2013; 32(17):2220-2229. https://doi.org/10.1038/onc.2012.231 PMID: 22689061
60. Serizawa M, Takahashi T, Yamamoto N, Koh Y. Combined treatment with erlotinib and a transforming growth factor-beta type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. J Thorac Oncol. 2013; 8(3):259-269. https://doi.org/10.1097/JTO.0b013e318279e942 PMID: 23334091
61. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim Js, et al. A novel signaling pathway impact analysis. Bioinformatics. 2009; 25(1):75-82. https://doi.org/10.1093/bioinformatics/btn577 PMID: 18990722
62. Huang daW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. https://doi.org/10.1038/nprot.2008.211 PMID: 19131956
63. Chang JT, Nevins JR. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics. 2006; 22(23):2926-2933. https://doi.org/10.1093/bioinformatics/btl483 PMID: 17000751
64. Han J, Shi X, Zhang Y, Xu Y, Jiang Y, Zhang C, et al. ESEA: Discovering the Dysregulated Pathways based on Edge Set Enrichment Analysis. Sci Rep. 2015; 5:13044. https://doi.org/10.1038/srep13044 PMID: 26267116
65. Han J, Li C, Yang H, Xu Y, Zhang C, Ma J, et al. A novel dysregulated pathway-identification analysis based on global influence of within-pathway effects and crosstalk between pathways. J R Soc Interface. 2015; 12(102):20140937. https://doi.org/10.1098/rsif.2014.0937 PMID: 25551156
66. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009; 69(17):6871-6878. https://doi.org/10.1158/0008-5472.CAN-08-4490 PMID: 19671800
67. Karakashev SV, Reginato MJ. Hypoxia/HIF-alpha induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. Oncotarget. 2015; 6(4):1967-1980. https://doi.org/10.18632/oncotarget.2806 PMID: 25596742
68. Xia W, Bacus S, Husain I, Liu L, Zhao S, Liu Z, et al. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol Cancer Ther. 2010; 9(2):292-299. https://doi.org/10.1158/1535-7163.MCT-09-1041 PMID: 20124457
69. Lynch MA, Petrel TA, Song H, Knobloch TJ, Casto BC, Ramljak D, et al. Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-betatype II receptor in human breast cancer cells. Gene Expr. 2001; 9(4-5):157-171. https://doi.org/10.3727/000000001783992560 PMID: 11444526
70. Serra V, Eichhorn PJ, Garcia-Garcia C, Ibrahim YH, Prudkin L, Sanchez G, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013; 123(6):2551-2563. https://doi.org/10.1172/JCI66343 PMID: 23635776
71. Hegde PS, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R, et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther. 2007; 6(5):1629-1640. https://doi.org/10.1158/1535-7163.MCT-05-0399 PMID: 17513611
72. Liu NN, Xi Y, Callaghan MU, Fribley A, Moore-Smith L, Zimmerman JW, et al. SMAD4 is a potential prognostic marker in human breast carcinomas. Tumour Biol. 2014; 35(1):641-650. https://doi.org/10.1007/s13277-013-1088-1 PMID: 23975369
73. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G, et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006; 66(4):2202-2209. https://doi.org/10.1158/0008-5472.CAN-05-3560 PMID: 16489022
74. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013; 41(Database issue):D955-961. https://doi.org/10.1093/nar/gks1111 PMID: 23180760
75. Hu J, Rho HS, Newman RH, Zhang J, Zhu H, Qian J. PhosphoNetworks: a database for human phosphorylation networks. Bioinformatics. 2014; 30(1):141-142. https://doi.org/10.1093/bioinformatics/btt627 PMID: 24227675
76. Khalil S, Tan GA, Giri DD, Zhou XK, Howe LR. Activation status of Wnt/beta-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS ONE. 2012; 7(3):e33421. https://doi.org/10.1371/journal.pone.0033421 PMID: 22457761
77. Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB. Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS ONE. 2013; 8(7):e67811. https://doi.org/10.1371/journal.pone.0067811 PMID: 23861811
78. Sasaki T, Suzuki H, Yagi K, Furuhashi M, Yao R, Susa S, et al. Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor beta-induced repression of c-myc. Cancer Res. 2003; 63(4):801-806. PMID: 12591729
79. Maglott DR, Katz KS, Sicotte H, Pruitt KD. NCBI's LocusLink and RefSeq. Nucleic Acids Res. 2000; 28(1):126-128. https://doi.org/10.1093/nar/28.1.126 PMID: 10592200
80. Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol. 1999; 189(2):194-200. https://doi.org/10.1002/(SICI)1096-9896(199910)189:2%3C194::AID-PATH426%3E3.0.CO;2-P PMID: 10547574
81. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol. 2002; 22(22):7842-7852. https://doi.org/10.1128/MCB.22.22.7842-7852.2002 PMID: 12391153
82. Qin H, Chan MW, Liyanarachchi S, Balch C, Potter D, Souriraj IJ, et al. An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules. BMC Syst Biol. 2009; 3:73. https://doi.org/10.1186/1752-0509-3-73 PMID: 19615063
83. Kanehisa M. The KEGG database. Novartis Found Symp. 2002; 247:91-101. https://doi.org/10.1002/0470857897.ch8 PMID: 12539951
84. Kechagioglou P, Papi RM, Provatopoulou X, Kalogera E, Papadimitriou E, Grigoropoulos P, et al. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression. Anticancer Res. 2014; 34(3):1387-1400. PMID: 24596386
85. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008; 68(22):9221-9230. https://doi.org/10.1158/0008-5472.CAN-08-1740 PMID: 19010894
86. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Friedecky D, Hajduch M. Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010; 154(4):281-288. https://doi.org/10.5507/bp.2010.043 PMID: 21293538
87. Du G, Bian L, Wang T, Xu X, Zhang S, Guo Y, et al. [PTEN loss correlates withthe clinical efficacy of lapatinib in HER2 positive metastatic breast cancer with trastuzumab-resistance]. Zhonghua Yi Xue ZaZhi. 2015; 95(28):2264-2267. PMID: 26710948
88. Carpenter RL, Lo HW. Regulation of Apoptosis by HER2 in Breast Cancer. Journal of Carcinogenesis & Mutagenesis. 2013; 0(0):1-7. https://doi.org/10.4172/2157-2518.S7-003 PMID: 27088047
89. Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL, Harari PM. p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res. 2011; 71(22):7071-7079. https://doi.org/10.1158/0008-5472.CAN-11-0128 PMID: 22068033
90. Boeckx C, Baay M, Wouters A, Specenier P, Vermorken JB, Peeters M, et al. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. Oncologist. 2013; 18(7):850-864. https://doi.org/10.1634/theoncologist.2013-0013 PMID: 23821327
91. Han C, Zhao R, Liu X, Srivastava A, Gong L, Mao H, et al. DDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer. Mol Cancer Res. 2014; 12(5):784-794. https://doi.org/10.1158/1541-7786.MCR-13-0638 PMID: 24574518
92. Ennen M, Klotz R, Touche N, Pinel S, Barbieux C, Besancenot V, et al. DDB2: a novel regulator of NF-kB and breast tumor invasion. Cancer Res. 2013; 73(16):5040-5052. https://doi.org/10.1158/0008-5472.CAN-12-3655 PMID: 23774208
93. Kattan Z, Marchal S, Brunner E, Ramacci C, Leroux A, Merlin JL, et al. Damaged DNA binding protein 2 plays a role in breast cancer cell growth. PLoS ONE. 2008; 3(4):e2002. https://doi.org/10.1371/journal.pone.0002002 PMID: 18431487
94. He YH. Involvement of DDB2 Down-regulation in Lapatinib-induced Cross-resistance to Chemotherapy. Ph.D. Thesis, National Digital Library of Theses and Dissertations in Taiwan; 2012. Available from: http://handle.ncl.edu.tw/11296/ndltd/06833793361974888604
95. Nieto-Sampedro M, Valle-Argos B, Gomez-Nicola D, Fernandez-Mayoralas A, Nieto-Diaz M. Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol. 2011; 5:265-314. https://doi.org/10.4137/CMO.S7685 PMID: 22084619
96. Wee KB, Surana U, Aguda BD. Oscillations of the p53-Akt network: implications on cell survival and death. PLoS ONE. 2009; 4(2):e4407. https://doi.org/10.1371/journal.pone.0004407 PMID: 19197384
97. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficienttumorigenesis. Nature. 2005; 436(7051):725-730. https://doi.org/10.1038/nature03918 PMID: 16079851
98. Sun NK, Sun CL, Lin CH, Pai LM, Chao CC. Damaged DNA-binding protein 2 (DDB2) protects against UV irradiation in human cells and Drosophila. J Biomed Sci. 2010; 17:27. https://doi.org/10.1186/1423-0127-17-27 PMID: 20398405
99. Carson C, Omolo B, Chu H, Zhou Y, Sambade MJ, Peters EC, et al. A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines. Pigment Cell Melanoma Res. 2012; 25(4):514-526. https://doi.org/10.1111/j.1755-148X.2012.01010.x PMID: 22540896
100. Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A, et al. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS ONE. 2011; 6(2):e16694. https://doi.org/10.1371/journal.pone.0016694 PMID: 21364753
101. Awan A, Bari H, Yan F, Moksong S, Yang S, Chowdhury S, et al. Regulatory network motifs and hot-spots of cancer genes in a mammalian cellular signalling network. IET Syst Biol. 2007; 1(5):292-297. https://doi.org/10.1049/iet-syb:20060068 PMID: 17907678
102. Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol Syst Biol. 2007; 3:140. https://doi.org/10.1038/msb4100180 PMID: 17940530
103. Guney E, Sanz-Pamplona R, Sierra A, Oliva B. In: Azmi AS, editor. Understanding Cancer Progression Using Protein Interaction Networks. Dordrecht: Springer Netherlands; 2012. p. 167-195.
104. Wang E. COSMIC: Cancer Gene census; 2017. Available from: http://cancer.sanger.ac.uk/census/
105. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer. 2004; 4(3):177-183. https://doi.org/10.1038/nrc1299 PMID: 14993899
106. Cerami E, Demir E, Schultz N, Taylor BS, Sander C. Automated network analysis identifies core pathways in glioblastoma. PLoS ONE. 2010; 5(2):e8918. https://doi.org/10.1371/journal.pone.0008918 PMID: 20169195
107. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2014; 42(Database issue):D472-477. https://doi.org/10.1093/nar/gkt1102 PMID: 24243840
108. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences. 2005; 102(43):15545-15550. https://doi.org/10.1073/pnas.0506580102 PMID: 16199517
109. Kelder T, van Iersel MP, Hanspers K, Kutmon M, Conklin BR, Evelo CT, et al. WikiPathways: building research communities on biological pathways. Nucleic Acids Res. 2012; 40(Database issue):D1301-1307. https://doi.org/10.1093/nar/gkr1074 PMID: 22096230
110. Wasserman S, Pattison P. Logit models and logistic regressions for social networks: I. An introduction to Markov graphs and p. Psychometrika. 1996; 61(3):401-425. https://doi.org/10.1007/BF02294547
111. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian Modelling Framework: Concepts, Structure, and Extensibility. Statistics and Computing. 2000; 10(4):325-337. https://doi.org/10.1023/A:1008929526011
112. Adams S, Carter N, Hadlock C, Haughton D, Sirbu G. Change in connectivity in asocial network over time: A bayesian perspective. Connections. 2008; 28:17-27.
113. Han J, Shi X, Zhang Y, Xu Y, Jiang Y, Zhang C, et al. ESEA: Discovering the Dysregulated Pathways based on Edge Set Enrichment Analysis. Sci Rep. 2015; 5:13044. https://doi.org/10.1038/srep13044 PMID: 26267116